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Abstract
Superagonistic CD28 antibodies (CD28SAs) activate T lymphocytes without concomitant perturbation of the TCR/CD3-
complex. In rodents these reagents induce the preferential expansion of regulatory T cells and can be used for the
treatment of autoimmune diseases. Unexpectedly, the humanized CD28 superagonist TGN1412 caused severe and life
threatening adverse effects during a recently conducted phase I clinical trail. The underlying molecular mechanisms are as
yet unclear. We show that TGN1412 as well as the commercially available CD28 superagonist ANC28.1 induce a delayed but
extremely sustained calcium response in human naı ¨ve and memory CD4
+ T cells but not in cynomolgus T lymphocytes. The
sustained Ca
++-signal was associated with the activation of multiple intracellular signaling pathways and together these
events culminated in the rapid de novo synthesis of high amounts of pro-inflammatory cytokines, most notably IFN-c and
TNF-a. Importantly, sustained transmembranous calcium flux, activation of Src-kinases as well as activation of PI3K were
found to be absolutely required for CD28SA-mediated production of IFN-c and IL-2. Collectively, our data suggest a
molecular basis for the severe side effects caused by TGN1412 and impinge upon the relevance of non-human primates as
preclinical models for reagents that are supposed to modify the function of human T cells.
Citation: Waibler Z, Sender LY, Merten C, Hartig R, Kliche S, et al (2008) Signaling Signatures and Functional Properties of Anti-Human CD28 Superagonistic
Antibodies. PLoS ONE 3(3): e1708. doi:10.1371/journal.pone.0001708
Editor: Derya Unutmaz, New York University School of Medicine, United States of America
Received December 19, 2007; Accepted January 24, 2008; Published March 5, 2008
Copyright:  2008 Waibler et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by a grant from the German Research Foundation (DFG) to B.S. and to U.K. (SFB432, B15). The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: kalul@pei.de (UK); Burkhart.Schraven@med.ovgu.de (BS)
. These authors contributed equally to this work.
Introduction
According to the currently accepted model of T cell activation,
two signals are required to fully activate resting naı ¨ve T
lymphocytes. The primary signal is provided by the clonotypic
T cell receptor (TCR) after recognition of antigen/MHC-
complexes on the surface of antigen presenting cells. However,
this signal by itself is not capable of fully activating T lymphocytes
but has to be complemented by secondary signals which emerge
from stimulation of so called co-stimulatory molecules [1,2]. In
mouse and human T cells the dimeric transmembrane glycopro-
tein CD28 represents the most important co-stimulatory molecule.
Under physiological conditions CD28-derived signals alone are
not capable of inducing T cell activation, whereas simultaneous
engagement of the TCR and CD28 (e.g. by its natural ligands
CD80 and CD86 which are expressed on mature antigen
presenting cells) leads to activation of resting T lymphocytes
(reviewed in [3,4]).
Monoclonal antibodies (mAbs) directed to the extracellular
domain of CD28 have been widely used during the last two
decades to analyze CD28-mediated signaling pathways and to
assess how CD28 facilitates activation and differentiation of
murine, rat, and human T lymphocytes. Most recently a particular
group of CD28 mAbs has been identified which is capable of
activating T cells without the need for additional engagement of
the TCR/CD3-complex [5–7]. These antibodies have collectively
been termed mitogenic CD28 antibodies or CD28 superagonists.
While conventional CD28 mAbs bind CD28 close to the binding
site of the natural CD28 ligands, CD80 and CD86, CD28
superagonists bind to a laterally exposed loop within the
extracellular domain of CD28 [8]. The particular binding
topology of superagonistic CD28 antibodies (CD28SAs) might
be responsible for their mitogenic potential.
A number of detailed biochemical studies in rat and mice
addressed the question how CD28SA-mediated signaling is
organized on the molecular level [5,6,8–13]. The emerged data
can be summarized as follows: (i) the signaling capacity of
CD28SAs depends on the expression of a functional TCR/CD3/
f-complex; (ii) CD28SA-stimulation does not lead to detectable
phosphorylation/activation of the TCRf chain or the proximal
TCR-effector molecules ZAP70 and LAT, but still induces
phosphorylation of the adapter protein SLP76 and the nucleotide
exchange factor Vav (likely via the Tec-family protein tyrosine
kinases Itk or Rlk); (iii) CD28SA-stimulation activates PLCc1
(phospholipase Cc1) and induces calcium flux, and (iv) CD28SA-
stimulation activates PKC h (protein kinase C h) as well as the
transcription factors NF-kB, NF-ATc1, and GATA-3.
Studies in rat and mice have also shown that CD28 super-
agonists preferentially induce the expansion of regulatory T cells
and therefore suggested that these antibodies can be used for the
treatment of autoimmune diseases such as experimental autoim-
mune encephalomyelitis [13–20]. Based on the promising data in
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applicable for the treatment of human autoimmune disorders.
However, when applied to healthy volunteers during a phase I
clinical trial performed on March 13
th, 2006 in London, UK, the
humanized CD28 superagonist TGN1412 showed unexpected
serious adverse events. These were associated with the induction of
a cytokine storm, i.e. the release of high amounts of pro-
inflammatory cytokines, most notably TNF-a and IFN-c [21].
The molecular basis for the unexpected response upon
treatment with the CD28 superagonist TGN1412 is as yet unclear.
To shed light on this question, we here addressed membrane
proximal signaling events in human T cells upon stimulation with
two different CD28 superagonists. We show that, despite complete
conservation of the CD28 extracellular and cytoplasmic domains,
TGN1412 and a commercially available CD28SA, ANC28.1/
5D10, induced a delayed but extremely sustained calcium
response in human, but not in cynomolgus and rhesus monkey
T cells. Biochemical analyses further revealed that both CD28SAs
strongly activated a number of major T cell signaling pathways in
human T cells. Together these signals culminate in the in vitro
production of high amounts of IFN-c, TNF-a, and other pro-
inflammatory cytokines.
Our experiments contribute to the understanding of the
particular pharmacologic properties of human CD28 super-
agonists and further suggest that currently available animal models
do not necessarily correctly reproduce critical signaling mecha-
nisms of human T cells.
Results
Mitogenicity of anti-human CD28 superagonist ANC28.1
By definition, CD28 superagonists induce polyclonal T cell
activation in vitro without the need of concomitant stimulation of
the TCR/CD3 complex [5,7]. We assessed the mitogenicity of a
commercially available CD28 superagonist (ANC28.1). In contrast
to stimulation of human T cells with the conventional CD28
antibody 248.23.2 [22], ANC28.1 was able to induce T cell
proliferation without additional stimulation via CD3 (Fig. 1A),
thus fulfilling the criteria of a CD28 superagonist. Note that
ANC28.1 still exerted costimulatory properties as it strongly
augmented the proliferative response of T cells stimulated with
CD3 antibody (Fig. 1A).
Previously, several groups have assessed the signaling events
induced by anti-rat or anti-mouse CD28 superagonistic antibodies
[5,6,8,11–13]. In contrast, only few data are available regarding
the signaling properties of anti-human CD28 superagonists. To
explore the signaling properties of ANC28.1, phosphospecific
western blots were performed (Fig. 1B). The transmembrane
adapter protein LAT (Linker for Activation of T cells) represents a
35 kDa polypeptide that is essential for T cell activation [23,24].
Upon TCR-mediated phosphorylation of four critical tyrosine
residues, LAT assembles a multi-component signaling complex
consisting of the cytosolic adapter proteins Gads (Grb2-related
adaptor downstream of Shc) and SLP76 (SH2 domain containing
leucocyte specific phosphoprotein of 76 kDa), the Tec-family
protein tyrosine kinase Itk (Inducible T-cell kinase), and PLCc1
(Phospholipase Cc1; reviewed in [25]). This complex is responsible
for the rise in intracellular calcium upon stimulation of the TCR.
We first employed a phosphospecific antibody that detects one of
the major tyrosine phosphorylation sites within LAT, Y
171.A s
shown in Fig. 1B, upper panel, ANC28.1 induced a weak but
clearly detectable phosphorylation of Y
171. Similar data were
obtained when the phosphorylation status of Y
136, one of several
additional phosphorylation sites of LAT, was assessed (data not
shown). Hence, in contrast to rat T cells, anti-human CD28
superagonist ANC28.1 induced a weak but clearly detectable
phosphorylation of LAT. Interestingly and in line with previous
data obtained in human and rat T cells [8,12], ANC28.1
stimulation did not result in a detectable phosphorylation (a sign
for activation) of the protein tyrosine kinase ZAP70 which is
believed to be primarily responsible for LAT phosphorylation
upon TCR-stimulation (Fig. 1B, middle panel).
Upon engagement of the TCR/CD3-complex, phosphorylated
LAT facilitates the activation of PLCc1 which in turn generates
the second messenger molecules IP3 (Inositol-tris-phosphate) and
DAG (Diacyloglycerol; reviewed in [25]). To assess whether the
moderate phosphorylation of LAT induced by ANC28.1 was
sufficient to activate PLCc1, we investigated the phosphorylation
status of Y
783 of PLCc1 which correlates with its enzymatic activity
[26]. The lower panel of Fig. 1B demonstrates that similar to rat T
Figure 1. The CD28 superagonist ANC28.1 induces polyclonal T
cell activation in vitro and leads to ZAP70 independent
phosphorylation of LAT and PLCc1. (A) 5610
4 freshly prepared
human T cells per well were seeded in 96-well plates and treated with
the indicated combinations of antibodies or were incubated in medium
as a control. 72 hours after stimulation, cultures were pulsed with
3H-
thymidine for 6 hours and harvested thereafter. Note that ANC28.1 only
induces polyclonal T cell proliferation when applied in soluble form (in
this case 10 mg/ml of soluble ANC28.1 were crosslinked in solution with
20 mg/ml of polyclonal goat-anti-mouse antiserum). All other stimula-
tions (including stimulation of T cells with CD3e mAb and ANC28.1; very
right bar in Fig. 1A) were performed in wells that were pre-coated with
polyclonal goat anti-mouse antiserum. Shown data are representative
for at least 6 independently performed experiments. (B) 1610
6 freshly
prepared human T cells/lane were stimulated in solution with 10 mg/ml
ANC28.1 followed by crosslinking with 20 mg/ml polyclonal goat anti-
mouse antiserum for the indicated periods of time. As a control, cells
were activated with a 1:50 v/v dilution of ascites fluid of CD3e mAb
MEM92 (IgM) or were left untreated. Cell lysates were processed for
western blotting using the indicated phosphospecific antibodies (Y
319
of ZAP70, Y
171 of LAT, and Y
783 of PLCc1). Western blotting using an
anti-actin antibody was performed as loading control.
doi:10.1371/journal.pone.0001708.g001
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sustained activation of PLCc1 when compared to stimulation of
human T cells with CD3 mAb. Thus, ANC28.1 induced a
phosphorylation pattern that was different from the one obtained
when human T cells were activated via CD3.
Sustained calcium flux upon T cell stimulation with
superagonistic ANC28.1
The different activation kinetics of PLCc1 produced by CD3 vs.
CD28 superagonist ANC28.1 were translated into corresponding
Ca
++-responses (Fig. 2A). Thus, independently of the concentra-
tions used the CD3e mAbs MEM92 (Fig. 2A, upper panel and Fig.
S1) and OKT3 (Fig. S1 and [27]) induced a rapid, strong, and
transient rise in intracellular Ca
++ whereas the CD28SA-mediated
Ca
++-signal started delayed and was of lower intensity (Fig. 2A,
lower panel). Surprisingly, an extended analysis revealed that the
CD28SA-mediated Ca
++-signal had an extremely sustained
kinetics (Fig. 2A–2F) that lasted for more than six hours without
significant decrease (Fig. S2).
The flow cytometric data obtained with Indo-1 labeled T cells
were confirmed by live time video microscopy of T cells loaded
with the calcium sensitive dye Fura2 (Movie S1 and Movie S2).
Note that stimulation of the same cells with two conventional
CD28 mAbs (CD28.2, Fig. 2A, middle panel and 248.23.2, data
not shown) did not induce any detectable Ca
++-signal either with
or without crosslinking.
Downmodulation of the TCR by treatment of T cells with the
CD3e mAb 2AD2A2 [28] (Fig. 2B, TCR
dull T cells) or pre-
treatment of T cells with the Src-kinase inhibitor PP2 (Fig. 2C,
lower panel) completely abrogated the ANC28.1-mediated
calcium response, whereas pharmacologic inhibition of PI3K by
Wortmannin had almost no effect (Fig. 2C, middle panel). Hence,
similar to the situation in rat T cells [11,12] expression of a
functional TCR and the activation of Src-kinases are required for
ANC28.1-mediated calcium flux, whereas activation of PI3K
appears to be dispensable. Further stimulation experiments in the
presence of the calcium-chelator EGTA revealed that the
ANC28.1-mediated Ca
++-signal required the presence of extra-
cellular calcium ions (Fig. 2D).
Importantly, after inducing the expected peak (compare Fig. 2A,
upper panel), addition of a conventional CD3 mAb to CD28SA-
stimulated T cells abrogated the sustained Ca
++-flux (Fig. 2E). This
might suggest that CD3 stimulation activates a negative feedback
loop that is otherwise not activated upon CD28SA-stimulation.
We next assessed which T cell population preferentially
responded to CD28SA stimulation. As expected from published
work [29,30] ANC28.1 induced a stronger Ca
++-signal in CD4
+ T
cells compared to CD8
+ T cells (Fig. 2F, left panels) whereas
almost no differences were observed between CD4
+/CD45RA
+
naı ¨ve vs. CD4
+/CD45RO
+ memory T lymphocytes (Fig. 2F, right
panels).
Induction of T cell proliferation and sustained calcium
flux by CD28 superagonist TGN1412
To exclude the possibility that the induction of a sustained
calcium signal was a particular property of ANC28.1, we repeated
the experiment shown in Fig. 2A using the superagonistic CD28-
specific antibody TGN1412. Fig. 3A depicts that TGN1412
generated a similarly shaped calcium signature as antibody
ANC28.1 although it induced a calcium response only upon
crosslinking. In addition, the magnitude of the calcium response
elicited by TGN1412 was generally lower than that of ANC28.1.
The weaker signaling properties of TGN1412 compared to the
ANC28.1 were also reflected by a generally lower mitogenic
potential of TGN1412 (Fig. 3B).
Intracellular signaling events induced by ANC28.1 and
TGN1412
Given the sustained calcium response induced by ANC28.1 and
TGN1412 we next investigated the consequences of CD28SA
stimulation on downstream signaling events using reporter
antibodies that monitor the activity of key signaling molecules
involved in T cell activation. The first and third panels of Fig. 3C
demonstrate that mAb ANC28.1 induced a delayed, strong, and
sustained activation of all signaling events we investigated (Erk1/2,
JNK, p38, AKT, GSK3b-1, NF-ATc1, and IkBa). Of note,
ANC28.1 induced an even stronger activation of JNK, p38, AKT,
and IkBa compared to CD3 mAb (second panel), whereas
activation of Erk1/2 and dephosphorylation of the transcription
factor NF-ATc1 were less pronounced. Similar results as for
ANC28.1 were obtained when cells were stimulated with
TGN1412 (Fig. 3C, right panel). However, in line with the lower
magnitude of Ca
++-signaling and the weaker induction of a
proliferative response, the phosphorylation signals induced by
TGN1412 were generally less pronounced than those induced by
ANC28.1. In multiple experiments, both ANC28.1 and TGN1412
induced a sharp initial rise of p38 phosphorylation which
transiently dropped after 5 minutes of stimulation. The reason
for this particular phosphorylation signature is yet unknown. Note
that a conventional CD28 antibody only induced the known
activation of the AKT and the JNK pathways (data not shown and
[31]). In summary, both human CD28 superagonists not only
produced a sustained induction of Ca
++-flux but also an activation
of multiple intracellular signaling pathways.
In vitro cytokine production upon conventional vs.
superagonistic human T cell stimulation
Within hours after administration of TGN1412 to six healthy
individuals, clinical symptoms became apparent that were
consistent with a massive cytokine storm mediated by the release
of TH1- and TH2-specific cytokines [21]. In line with previous
data obtained using TGN1412 [32] Fig. 4 shows that also in vitro
human T cells respond upon ANC28.1- or TGN1412-mediated
stimulation with a strong production of high amounts of the pro-
inflammatory cytokines IFN-c, TNF-a, IL-2, -4, -5, and anti-
inflammatory IL-10. In all experiments we observed that at the
chosen concentration, TGN1412 was a better inducer of IL-10
than ANC28.1. In contrast (and in agreement with the generally
stronger signals elicited by ANC28.1), the amounts of TNF-a,
IFN-c, IL-2, and IL-4 were higher upon stimulation with
ANC28.1. Nevertheless, at concentrations inducing similar levels
of proliferation, both CD28 superagonists induced the synthesis of
significantly higher levels of cytokines compared to conventional
CD3/CD28 co-stimulation. Hence, the activation of multiple
signaling pathways upon CD28SA-mediated T cell activation is
translated into a corresponding in vitro cytokine response.
Fig. 5A depicts that similar to the situation in vivo, IFN-c
secretion occurred very rapidly after CD28SA stimulation. This
allowed us to use pharmacological inhibitors to further dissect the
molecular requirements leading to CD28SA-mediated IFN-c
production. Fig. 5B shows that incubation of T cells with
cycloheximide, PP2, and Cyclosporin A (CSA) completely
abrogated ANC28.1-mediated IFN-c production. Hence, IFN-c
secretion upon CD28SA stimulation is due to de novo protein
synthesis. Further, it requires activity of Src-kinases and involves
the Calcineurin/NF-AT-mediated signaling pathway.
Anti-Human CD28 Superagonists
PLoS ONE | www.plosone.org 3 March 2008 | Volume 3 | Issue 3 | e1708Figure 2. Induction of sustained calcium flux by human CD28 superagonistic antibody ANC28.1. (A) 1610
6 freshly prepared Indo-1
loaded human T cells were stimulated with either a 1:50 v/v dilution of ascites fluid of CD3 mAb MEM92 (orange triangle), 10 mg/ml conventional
CD28 mAb (CD28.2; blue triangle) followed by crosslinking with 20 mg/ml polyclonal goat anti-mouse antiserum (black triangle) or 10 mg/ml ANC28.1
(red triangle) followed by crosslinking with 20 mg/ml polyclonal goat anti-mouse antiserum (black triangle). Induction of the Ca
++-response was
monitored for approximately 75 minutes. Note that using another conventional anti-CD28 mAb (248.23.2; with or without crosslinking) no Ca
++-flux
was induced as well (data not shown). (B) Untreated (untreated T cells) or 2AD2A2 pre-treated (TCR
dull T cells) human T cells were stimulated with
ANC28.1 (red triangles) and subsequently crosslinked (black triangles) as described in (A) and induction of the Ca
++-response was monitored for the
indicated periods of time. To confirm proper loading of the cells with Indo-1, the Ca
++-ionophore Ionomycin (10 mg/ml) was added at the end of the
experiment (unfilled triangle). (C) Cells were treated with ANC28.1 (red triangles) followed by crosslinking (black triangles) as described in (A) in the
absence (no inhibitor) or presence of the PI3-kinase inhibitor Wortmannin (0.2 mM) or the Src-kinase inhibitor PP2 (10 mM). (D) CD3 (orange triangle)
or ANC28.1 (red triangle) stimulation plus crosslinking (black triangle) was performed as described in (A) in culture medium that was supplemented
with 1 mM EGTA to chelate extracellular Ca
++ ions (solid arrow). At the indicated time points CaCl2 was added at a final concentration of 2 mM
(dashed arrow). (E) Cells were treated with ANC28.1 as described in Fig. 1A. Additionally, at about 1 h of Ca-flux, a 1:50 v/v dilution of ascites fluid of
CD3 mAb MEM92 (orange triangle) was added. (F) CD8
+, CD4
+, CD4
+/CD45RA
+ naı ¨ve, and CD4
+/CD45RO
+ memory T lymphocytes were treated with
ANC28.1 as described in (A) and induction of the Ca
++-response was monitored for approximately 150 minutes.
doi:10.1371/journal.pone.0001708.g002
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calcium ions by EGTA completely abrogated IFN-c production
after ANC28.1 stimulation. This finding shows that transmem-
branous calcium flux is mandatory for CD28SA-mediated
induction of cytokine synthesis. Note that addition of extracellular
Ca
++ ions to EGTA-treated cells completely restored the
CD28SA-induced IFN-c response (Fig. 5B), excluding toxic
EGTA effects.
Above we showed that the PI3K inhibitor Wortmannin did not
influence CD28SA-mediated calcium flux (Fig. 2C). Similarly,
neither Wortmannin nor a second PI3K inhibitor, LY294002,
influenced CD28SA-mediated phosphorylation of SLP76, Vav,
Erk, JNK, p38, the degradation of IKK or the dephosphorylation
of NF-ATc1 (Fig. 5C), whereas both inhibitors completely
abrogated CD28SA-mediated phosphorylation of AKT (upper
panel in Fig. 5C). These data corroborate a recent report showing
Figure 3. Sustained calcium flux, T cell proliferation, and T cell signaling upon TGN1412 treatment. (A) Freshly isolated human T cells
were treated as described in Fig. 2 using the superagonistic CD28 specific mAb TGN1412 (10 mg/ml; red triangle). For crosslinking, 20 mg/ml of
monoclonal mouse anti-human IgG4 was used (black triangle) and induction of the Ca
++-response was monitored. (B) 5610
4 freshly prepared human
T-cells/96-well were stimulated with the indicated concentrations of ANC28.1 or TGN1412 or were left untreated as a control. For crosslinking of
ANC28.1, a polyclonal goat anti-mouse antiserum was used and crosslinking of TGN1412 was performed as described in (A). Concentrations for
crosslinking were the following: 0.1–1.25 mg/ml primary Ab+2.5 mg/ml crosslinker; 2.5 mg/ml primary Ab+5 mg/ml crosslinker; 5 mg/ml primary
Ab+10 mg/ml crosslinker; 10 mg/ml primary Ab+20 mg/ml crosslinker. 72 hours after stimulation, cultures were pulsed with
3H-thymidine for 6 hours,
then harvested and proliferation analyzed by counts per minute [cpm]. (C) 1610
6 freshly prepared human T cells/lane were left untreated or were
stimulated with 10 mg/ml ANC28.1 (first and third panel) followed by crosslinking with 20 mg/ml polyclonal goat anti-mouse antiserum or with 10 mg/
ml TGN1412 (right panel) followed by crosslinking as described in (A) for the indicated periods of time. As a control, cells were activated with a 1:50
dilution of ascites fluid of CD3 mAb MEM92 (second panel). Postnuclear lysates were processed for western blotting using the indicated
phosphospecific antibodies. Western blotting using an anti-actin antibody was performed as loading control.
doi:10.1371/journal.pone.0001708.g003
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pretreated with Wortmannin or Ly294002 [33]. Surprisingly, both
Wortmannin and Ly294002 induced an almost complete block of
IFN-c production after ANC28.1 stimulation (Fig. 5B). This
suggests that PI3K or its downstream effector AKT [34,35] is
mandatory (although not sufficient) for CD28SA-mediated IFN-c
production.
We next assessed the mechanisms underlying CD28SA-
mediated IL-2 induction. This was of particular interest because
a recent report suggested that in rat T cells CD28SA induced IL-2
production might not require PI3K activity [12]. Fig. 5D shows
that, similar to IFN-c production, CD28SA-mediated IL-2
synthesis by human T cells was sensitive to treatment with EGTA,
cycloheximide, CSA, and PP2. Furthermore, Wortmannin and
LY294002 abrogated CD28SA-mediated IL-2 synthesis. Hence, in
contrast to rat T cells, activation of PI3K was also mandatory for
CD28SA induced IL-2 production by human T lymphocytes.
We finally assessed whether the sustained Ca
++ signaling that is
induced by ANC28.1 and TGN1412 (see Figs. 2 and 3) is required
for cytokine production upon CD28SA-stimulation. To achieve
Figure 4. Cytokine production upon conventional and superagonistic CD28 stimulation of human T cells. 5610
4 freshly prepared
human T-cells/96-well were stimulated with the indicated combination of antibodies as described in Fig. 1A or were left untreated as controls. At
48 hours 50 ml culture supernatant was removed from each well. Supernatants obtained from 3 wells were pooled and cytokine content was
determined using the Cytokine Bead Array from BD in signals per minute [spm] (black bars). Additionally, induction of T cell proliferation was
monitored upon treatment with the indicated antibody combinations (gray bars). 72 hours after stimulation, cultures were pulsed with
3H-thymidine
for 6 hours, then harvested and proliferation analyzed by counts per minute [cpm]. Data represent the mean of 5 individual experiments.
doi:10.1371/journal.pone.0001708.g004
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PLoS ONE | www.plosone.org 6 March 2008 | Volume 3 | Issue 3 | e1708Figure 5. Analysis of the signaling pathways controlling CD28SA-mediated IFN-c and IL-2 production. (A) Short term IFN-c production
upon CD28SA stimulation of T cells. 1610
6 T cells/200 ml were activated by CD28SA ANC28.1 as described for Figs. 1–4. At the indicated time points
50 ml of the supernatants were removed, diluted 1:3 v/v, and the concentration of secreted IFN-c was determined using a commercially available
ELISA. (B) Molecular requirements determining CD28SA-mediated IFN-c production. T cells were pretreated for 30 minutes with the indicated
substances prior to stimulation with ANC28.1. EGTA was used at 1 mM, CaCl2 at 2 mM, cycloheximide at 50 mg/ml, CSA at 150 ng/ml, PP2 at 10 mM,
Wortmannin at 0.1 mM, and Ly294002 at 20 mM. At the indicated time points cytokine production was determined as described in (A). (C) 1610
6
freshly prepared human T cells/lane were stimulated with 10 mg/ml ANC28.1 followed by crosslinking with 20 mg/ml polyclonal goat anti-mouse
antiserum with or without Wortmannin treatment. Western blotting was conducted as described in Fig. 3. Note that identical results were obtained
when T cells were pretreated with LY294002 (data not shown). (D) Molecular requirements determining CD28SA-mediated IL-2 production. T cells
were pretreated for 30 minutes with the indicated substances prior to stimulation with ANC28.1 as described in (B). 4 h after stimulation 50 ml of the
supernatants were removed, diluted 1:3 v/v, and the concentration of IL-2 was analyzed in supernatants by an ELISA. (E) CD28SA-mediated IFN-c and
IL-2 production requires sustained Ca
++-flux. T cells were stimulated with ANC28.1 as described above. At 159,3 0 9, 1 h, 2 h, 3 h, 4 h, and 5 h Ca
++-flux
was interrupted by addition of EGTA (1 mM) and the concentration of the cytokines in the supernatant was determined as described in (B) and (D).
The concentrations of IL-2 and IFN-c that were produced by ANC28.1-stimulated T cells following 6 hours of stimulation in the absence of EGTA were
set to 100%. All data shown in Fig. 5 are representative for three independently performed experiments.
doi:10.1371/journal.pone.0001708.g005
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PLoS ONE | www.plosone.org 7 March 2008 | Volume 3 | Issue 3 | e1708this we inhibited transmembranous Ca
++-flux at different time
points after stimulation with ANC28.1 by the addition of EGTA
and subsequently determined the concentration of IFN-c and IL-2
in the culture supernatants. Fig. 5E depicts that the amounts of
IFN-c and IL-2 secreted by CD28SA-stimulated T cells directly
correlated with the duration of CD28-mediated transmembranous
Ca
++-flux. Thus, sustained calcium flux is important for the strong
production of IFN-c and IL-2 upon CD28SA stimulation.
Lack of a TGN1412-mediated calcium response in
monkey T cells
Before being used in the London phase I clinical trial,
TGN1412 had been applied to rhesus and cynomolgus monkeys
without showing obvious severe adverse effects [36]. Furthermore,
it was debated whether the extracellular domains of Macaca
fascicularis (cynomolgus), Macaca mulatta (rhesus), and Homo sapiens
CD28 show subtle differences on the protein level [37] [38]. To
clarify the latter question we sequenced CD28 cDNAs obtained
from 14 individual rhesus and 11 cynomolgus monkeys and
compared the deduced amino acid sequences with the protein
sequence of human CD28. Notably, this approach corroborated
that the CD28 extracellular domains (as well as the cytoplasmic
tails) are completely conserved between the three species (Fig. S3).
Interestingly, in all 25 monkeys investigated we observed three
non-conservative amino acid exchanges in the transmembrane
region (Fig. S3). Furthermore, one non-conservative amino acid
exchange was found within the leader sequence of the non-human
primates.
The complete conservation of the extracellular domains of
CD28 across the investigated species was further reflected by
similar TGN1412 binding of human CD3
+ and non-human
primate CD3
+ T cells. A 1:1 mixture of CD3
+ human T cells
(stained with an anti-CD3-APC antibody) and CD3
+ non-human
primate T cells (stained with an anti-CD3-PE antibody) derived
from cynomolgus (Fig. 6A, left panel) or rhesus (Fig. 6A, right
panel) monkeys, respectively, was incubated with Alexa 488
labeled TGN1412 at graded concentrations. Similar decoration of
T cells from both species with TGN1412 indicated similar binding
capacities of human and non-human primate CD28 to the
antibody. Moreover, FACS analyses revealed a similar ratio of
CD4
+ vs. CD8
+ T cells in blood samples of human and non-
human origin (Fig. 6B).
Interestingly, despite similar TGN1412 binding, identical
extracellular CD28 domains of all three species, and a similar
ratio of CD4
+ vs. CD8
+ T cells in blood samples of human and
non-human origin (Fig. 6 and Fig. S3), TGN1412 only induced a
very low calcium signal in rhesus or cynomolgus T cells (Fig. 6C).
Similar results were obtained with ANC28.1 (data not shown).
Note that the profound differences in the Ca
++-response between
monkey and human T cells were also observed at higher
concentrations of both antibodies (up to 20 mg/ml; not shown).
Thus, despite comparable levels of CD28 expression and similar
reactivity with TGN1412 only human T cells are capable of
inducing a significant calcium response upon stimulation with
CD28 superagonists.
Discussion
The data shown in this report clearly demonstrate that two
superagonistic CD28 mAbs, TGN1412 and ANC28.1, generate a
remarkably sustained Ca
++-response when applied to human T
cells in vitro (Fig. 2 and 3). The prolonged Ca
++-signal is preceded
by a sustained activation of PLCc1 (Fig. 1) and is downstream
correlated with an activation of a number of different signaling
pathways (Fig. 3) that are involved in the activation and
differentiation of T lymphocytes. Together, these signals culminate
in the production of a variety of pro-inflammatory cytokines, most
notably IFN-c and TNF-a (Fig. 4).
The strong and sustained Ca
++-response elicited by the
CD28SAs seems to be a particular property of the human system
and it appears as if human T cells react more sensitive to CD28SA
stimulation compared to rat and monkey T cells ([11] and Fig. 6).
A sustained Ca
++-response following CD28SA-stimulation has
previously been described for rat T cells [11]. However, due to the
low on-rate or the weak accessibility of the CD28 epitope detected
by CD28SAs, the induction of Ca
++-flux in rat T cells required
antibody pre-incubation for several hours [11]. Similarly, the
induction of proliferation by mitogenic rat CD28SA antibodies
needs extensive crosslinking and we also observed that the binding
of an anti-mouse CD28SA (D665) to the surface of murine T cells
occurred with an extremely slow kinetics and was strongest upon
overnight incubation on ice (data not shown).
In contrast, the binding of both TGN1412 and ANC28.1 to
human T cells occurs rapidly and is almost indistinguishable from
the binding of monoclonal antibodies directed to other cell surface
receptors (data not shown). Hence, the binding of CD28SAs to
human T cells occurs with much faster kinetics compared to
mouse and rat CD28SAs. A faster on-rate (presumably combined
with a slow off-rate) could explain why CD28SAs are capable of
inducing sustained signaling in human T lymphocytes.
A number of previous studies had assessed the capability of
conventional CD28 antibodies to induce Ca
++-flux in Jurkat T
cells and primary human T cells. These studies suggested that
CD28-mediated Ca
++-flux requires extracellular calcium ions and
hence, is EGTA-sensitive [30]. However, they also suggested that
CD28-mediated signals do not activate the PTK pathway [30],
occur in the absence of TCR signals [30], do not lead to
production of DAG [39], and also do not activate PKC. This
appears not to be the case for the anti-human CD28SAs for the
following reasons: (i) we show that (similar to rat T cells [12]) the
Ca
++-signal produced by ANC28.1 required expression of a
functional TCR (Fig. 2B); (ii) anti-human CD28SA signaling was
Src protein tyrosine kinase dependent as it could be blocked by
PP2 (Fig. 2C); (iii) anti-human CD28SA-mediated signaling
induced the induction of the DAG-dependent Ras/Raf/Erk
pathway (Fig. 3C), and (iv) it led to activation of the IKK/NF-
kB pathway (Fig. 3C) which is dependent on activation of PKC.
Hence, despite some similarities, the signaling properties of
conventional anti-human CD28 antibodies fundamentally differ
from those of CD28 superagonists.
In agreement with data obtained in rat T cells [12], ANC28.1
stimulation did not result in a detectable tyrosine phosphorylation
of the protein tyrosine kinase ZAP70 (Fig. 1B, middle panel)
although ZAP70 is believed to be primarily responsible for LAT
phosphorylation upon TCR-stimulation. At present it is unclear
which protein kinase is responsible for LAT phosphorylation upon
CD28 superagonistic stimulation of human T cells. Attractive
candidates include the two Tec-family protein tyrosine kinases Itk
and Rlk [12].
An important question that needs to be addressed in the future
is why the calcium-signal induced by human superagonistic CD28
mAbs has such a dramatically prolonged kinetics. It is obvious
from our study that the potency of CD28SAs to activate PLCc1
and to induce Ca
++-flux is lower than the potency of CD3 mAb.
Thus, it is possible that the amount of IP3 generated upon
triggering by CD28SAs suffices to activate membrane associated
Ca
++-channels, but that the overall Ca
++ influx is below the
threshold that is needed to close the channels. In line with this idea
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the CD28SAs can be stopped by administration of a CD3 mAb
(Fig. 2E). However, further studies are required to elucidate the
question how transmembrane flux is induced and maintained
upon CD28SA-stimulation. Moreover, it will be important to
determine the functional roles of the recently identified ORAI1
and STIM proteins in CD28SA-induced transmembrane Ca
++-
flux [40].
Our data show that CD28SA-stimulation leads to a strong and
very rapid production of cytokines in vitro (Figs. 4 and 5). Indeed,
IFN-c was detectable in the culture supernatant already 90–
120 minutes after CD28SA stimulation (Fig. 5A). Inhibition of
protein synthesis by cycloheximide completely abrogated IFN-c
secretion (Fig. 5B) which strongly suggests that this event is not due
to a release of the cytokine from intracellular stores but rather due
to de novo IFN-c synthesis. Furthermore, the production of IFN-c
was dependent on CD28SA-mediated Ca
++-flux as pretreatment
of the cells with EGTA completely blocked the response. Perhaps
more importantly, our data show that the amounts of IFN-c and
IL-2 produced by CD28SA-treated cells directly depend on the
Figure 6. Despite similar TGN1412 binding, Macaca derived T cells show reduced calcium flux upon TGN1412 stimulation when
compared to human T cells. (A) MACS purified CD3
+ human T cells (stained with an anti-CD3-APC antibody) and CD3
+ monkey T cells (stained
with an anti-CD3-PE antibody) were mixed 1:1 and then incubated with graded concentrations of Alexa 488 labeled TGN1412. Binding of TGN1412-
Alexa 488 was monitored by FACS analysis. Numbers given indicate the mean fluorescence intensity of samples. (B) Ratio of CD4
+ vs. CD8
+ T cells
(gated on CD3
+ cells) of human and monkey blood samples was analyzed by FACS analyses. (C) 1610
6 freshly isolated Indo-1 loaded M. fascicularis
and M. mulatta T cells were treated as described in Fig. 2 using the superagonistic CD28 specific mAb TGN1412 (10 mg/ml; red triangle). For
crosslinking, 20 mg/ml monoclonal mouse anti-human IgG4 was used (black triangle) and induction of the Ca
++-response was monitored. To confirm
viability of cells and proper loading with Indo-1, Ionomycin (10 mg/ml) was added at the end of the experiment (unfilled triangle).
doi:10.1371/journal.pone.0001708.g006
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++-flux (Fig. 5E). Thus, it appears
as if the large amounts of cytokines produced upon anti-human
CD28SA-stimulation in vitro (and presumably also in vivo) are due
to the sustained Ca
++-signal generated by the CD28 superagonistic
antibodies.
With regard to the induction of IL-2 synthesis the signaling
properties of CD28 superagonists again appear to differ from those
of conventional CD28 mAbs. Based on studies using cholera-toxin,
it was suggested that conventional CD28 antibodies activate two
functionally unrelated signaling pathways [22]. One of these
pathways was found to be cholera-toxin sensitive, initiated
transmembranous Ca
++-flux, but did not influence IL-2 secretion
whereas the other one was cholera-toxin insensitive and
responsible for IL-2 production [22]. Both with regard to
production of IL-2 and IFN-c this mechanism does not hold true
for signaling induced by CD28SAs. Indeed, we show that both the
PTK/PLCc/Ca
++-pathway and the PI3-kinase pathway must
operate simultaneously in order to allow IL-2 and IFN-c synthesis.
Whether this also applies for the production of other cytokines
upon CD28SA stimulation requires further analysis. Moreover,
despite costimulatory capacity, the same antibody that was used by
Nunes et al. to dissect signaling events upon CD28-stimulation in
Jurkat T cells (mAb 248.23.2 [22]) did not generate a detectable
Ca
++ signal in primary human T cells (data not shown). These
differences might be due to the different cells that were
investigated or to different CD28 antibody preparations (ascites
fluid in [22] vs. cell culture supernatant in our study).
It is important to note that the signaling pathways induced by
CD28SAs also seem to differ between rat and human T cells. A
recent report suggested that IL-2 production upon CD28SA-
stimulation of rat T cells is primarily mediated via the SLP76/
Vav-module and does not require activation of PI3K [12]. The
latter assumption was based on the observation that anti-rat CD28
superagonists do not induce phosphorylation of AKT and that
mutation of the PI3K binding site within the cytoplasmic domain
of CD28 did not ablate CD28SA-mediated IL-2 production [12].
However, our data show that CD28-mediated IFN-c and IL-2
production required both transmembranous Ca
++-flux and
activation of PI3K (Fig. 5). Indeed, inhibition of PI3K blocked
CD28SA-mediated IL-2 production in human T cells without
influencing transmembranous Ca
++-flux, phosphorylation of
SLP76, Vav, Erk, JNK, p38 as well as the activation of the
transcription factors NF-AT and NF-kB. Together these data
suggest that anti-human CD28SA signaling involves at least
two major signaling modules, one that depends on activity of
PI3K and a second one that requires transmembranous Ca
++-flux
(note that treatment of T cells with EGTA did not substan-
tially alter CD28SA-mediated activation of AKT (data not
shown)). However, we certainly cannot exclude the possibility
that CD28SA-stimulation activates a pool of PI3K that does
not associate with CD28 upon CD28SA stimulation. Further, it
will be important to investigate whether PI3K regulates the
production of IL-2 and IFN-c upon CD28SA stimulation in
human T lymphocytes via its proposed downstream effector AKT
[34,35].
Differences between human and rodent T cell activation are
also underlined by experiments analyzing Ca
++-flux in CD4
+ and
CD8
+ T cell subpopulations. It was shown previously that in
mouse splenic T cells only CD4
+ but not CD8
+ T cells showed
Ca
++-flux upon CD28 triggering [29] whereas within human
PBMCs also CD8
+ cells were capable of Ca
++-release upon CD28
stimulation [30]. In agreement with data shown in this study
(Fig. 2F) responses by CD8
+ T cells were less pronounced than
those by CD4
+ T cells [30].
It is still unclear how CD28SAs precisely activate the multiple
intracellular signaling pathways at the level of the plasma
membrane. Initially we thought that this might be due to
formation of large CD28 clusters on the T cell surface. However,
in line with a recent report [33] we did not see obvious differences
in CD28 cluster formation upon CD28SA vs. CD28 stimulation
by confocal laserscanning microscopy (data not shown). However,
we cannot exclude the possibility that the assembly or the
dynamics of the recently identified microclusters [41] differs
between CD28 vs. CD28SA stimulation. It will be important to
assess this possibility in the future.
Although we observed that CD28SA stimulation led to the
activation of many intracellular signaling pathways it is important
to note that CD28SAs do not fully activate human T cells. For
example, we did not observe an activation of b1- or b2-integrins
upon CD28SA stimulation and we also did not see formation of F-
actin or induction of cell migration by CD28SAs (data not shown).
Why these cellular events are not initiated upon CD28SA
stimulation is unclear at present. One reason might be that the
thresholds that are required to activate these pathways are higher
than those regulating cytokine production.
The amino acid sequence of the extracellular domains of rhesus
and cynomolgus CD28 are identical with the one of human CD28
(Fig. S3 and see genebank entries 111144662 and 112817616 for
Macaca mulatta and 110611295, 111144664, and 110611297 for
Macaca fascicularis as well as ref. [42]). This was also reflected by
similar decoration of CD28 on T cells of human, Macaca mulatta,
and Macaca fascicularis origin with Alexa 488 labeled TGN1412
(Fig. 6A). Intriguingly however, monkey T cells did not show
Ca
++-response upon CD28SA stimulation (Fig. 6C) as it was
observed in human T cells. Unlike rodents, blood samples of non-
human primates and humans show approximately 70% T cells in
the lymphocyte gate and within the T cell population, non-human
primates and humans show a similar ratio of CD4
+ vs. CD8
+ T
cells (Fig. 6B and [43,44]). It is also important to note that the non-
human primates used in this study are not kept under specific
pathogen free (SPF) conditions although they are regularly
screened for infections with pathogens. Thus, the observation that
TGN1412 stimulation induced Ca
++-flux only in human but not in
non-human primate T cells (Fig. 6C) can not be explained by
significantly decreased numbers of CD4
+ T cells in non-human
primates or by a more naı ¨ve activation state of the T cells due to
SPF housing conditions.
Importantly, a recent study showed that chimpanzee T cells are
also less responsive towards in vitro stimulation than human T
cells and it was suggested that this might be due to loss of Siglec
expression on human T cells [45]. Siglecs are inhibitory receptors
that are related to CD33 and it appears as if their expression is lost
on T cells during evolution from monkey to human [45]. Hence,
the lack of Siglec expression might explain why human T cells
react more sensitive upon CD28SA stimulation compared to
Macaca T cells.
Alternatively, the number/size and/or distribution of lipid rafts
might differ between monkey and human T lymphocytes. Finally,
three non-conservative amino acid exchanges are present within
the transmembrane regions of Macaca monkey and human CD28
which might influence the lateral interactions between CD28 and
other signaling molecules within the plasma membrane. Clearly,
these points need to be investigated in the future.
Collectively, our functional and biochemical data provide a first
explanation for the severe adverse effects induced upon TGN1412
administration to human beings. Further, they show that in spite of
absence of toxicity signals in the Macaca model that is broadly
considered as the golden standard for preclinical tests, a detailed in
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inherently related with first-in-man studies.
Materials and Methods
Animals
Macaca mulatta (rhesus monkey) and Macaca fascicularis (cynomol-
gus monkey) were kept under conventional conditions at the
Central Animal Facility of the Paul-Ehrlich-Institut, Germany.
The animals are regularly screened for infections according the
recommendations of EUPRIM-Net including tuberculosis, alpha-
herpes virus, SIV, STLV, filovirus, and others. Experimental work
was carried out in compliance with regulations of German animal
welfare.
T cell purification
Peripheral blood mononuclear cells (PBMC) were isolated by
Ficoll gradient (Biochrom) centrifugation of heparinized blood
collected from healthy volunteers. Human T cells were further
purified by non-T cell depletion using the Pan T cell isolation kit II
(Miltenyi Biotec). For monkey T cell enrichment, monkey blood
was Ficoll purified using individually adjusted Ficoll dilutions
(between 95 and 100%). Then T cells were MACS purified using
the Pan T cell isolation kit for non-human primates (Miltenyi
Biotec). Human CD8
+, CD4
+, CD4
+/CD45RA
+ naı ¨ve, and
CD4
+/CD45RO
+ memory T lymphocytes were purified using
the CD4
+/CD8
+ T cell isolation kit and the CD4
+ naı ¨ve/memory
T cell isolation kit (Miltenyi Biotec).
Antibodies
For the different applications the following antibodies were
used: for cytokine release assays and proliferation assays the CD3e
monoclonal antibody OKT-3 (purchased from ATCC) was used
as hybridoma supernatant. Stimulations for western blotting
experiments and calcium release assays were performed using
the CD3e monoclonal antibody MEM92, kindly provided by Dr.
Vaclav Horejsi, Prague Academy of Sciences, Prague, Czech
Republic. For conventional co-stimulation, hybridoma superna-
tant of the CD28 monoclonal antibody 248.23.2 [22,46] or
commercially available CD28.2 (Biosciences) was used. The
superagonistic CD28 antibody ANC28.1/5D10 was obtained
from Ancell (referred to as ANC28.1 throughout the text) and
humanized superagonistic CD28 antibody TGN1412 was a gift
from Thomas Hanke.
In vitro proliferation assays
96-well round-bottomed tissue culture plates (Costar) were
coated with a 1:400 v/v dilution of polyclonal goat-anti-mouse
antiserum (specific for IgG and IgM, 50 ml/well). Plates were then
washed three times with phosphate buffered saline (Seromed) and
either 100 ml of CD3e mAb OKT-3 (1:2 v/v dilution of
hybridoma culture supernatant), 100 ml of conventional CD28
mAb 248.23.2 (1:2 v/v dilution of hybridoma culture supernatant)
or 100 ml of a 1:1 mixture of OKT-3 and 248.23.2 culture
supernatants were added. For CD3xANC28.1 induced prolifera-
tion 100 ml of a 1:2 v/v dilution of hybridoma culture supernatant
of CD3e mAb OKT-3 were supplemented with 10 mg/ml of
ANC28.1 were used. Alternatively, T cells were incubated with the
indicated concentrations of ANC28.1 or TGN1412 and cross-
linked with goat anti-mouse (IgG+IgM) polyclonal serum (Dia-
nova) or purified mouse anti-human IgG4 monoclonal antibody
(BD Pharmingen), respectively. For T cell proliferation experi-
ments, 5610
4 T cells/well were added in a final volume of 200 ml.
[3H]-thymidine (0.3 mCi/well; specific activity 50 Ci/mmol) was
added for the last 8–10 hours of the three day incubation and cells
were harvested using a PHD cell harvester. Thymidine incorpo-
ration was measured by liquid scintillation in counts per minute
[cpm].
In vitro cytokine production
Cells were stimulated in vitro in triplicates as described for T
cell proliferation. Approximately 48 hours after onset of the
stimulation 50 ml of culture supernatant was removed from each
well. Triplicate supernatants were pooled and 50 ml of each pool
was then used in the TH1/TH2/Inflammatory Cytometric Bead
Arrays (CBA) from Becton Dickenson according to the manufac-
turer’s recommendation. Cytokine expression is shown in signals
per minute [spm]. Data shown represent the mean of at least three
individual experiments.
To determine the concentration of IFN-c and IL-2 after short
term stimulation of T cells, the cell suspension was adjusted to
1610
5 T cells/200 ml. Cells were stimulated as described above
for the indicated periods of time. Subsequently, 50 ml culture
supernatant was removed and diluted 1:3 v/v in culture medium.
The concentrations of IFN-c and IL-2 were determined using the
Quantikine ELISA system from R&D Systems according to the
manufacturer’s recommendation. To assess the molecular require-
ments for CD28SA-mediated IFN-c and IL-2 production the
following inhibitors were used: EGTA (1 mM), CaCl2 (2 mM),
cycloheximide (50 mg/ml; Sigma), CSA (150 ng/ml; Calbiochem),
PP2 (10 mM; Calbiochem), Wortmannin (0.1 mM; Calbiochem),
and Ly294002 (20 mM; Calbiochem).
Western blotting
T cells were lysed in buffer containing 1% lauryl maltoside (N-
dodecyl b-maltoside), 1% NP-40, 1 mM Na3VO4, 1 mM PMSF,
10 mM NaF, 10 mM EDTA, 50 mM Tris pH 7.5, and 150 mM
NaCl. Postnuclear lysates were separated by SDS-PAGE and
transferred onto nitrocellulose membranes. Membranes were
probed with the indicated primary antibodies and the appropriate
HRP-conjugated secondary antibodies (Dianova) and developed
using the ECL detection system (Amersham Pharmacia). The
following antibodies were used for western blotting in this study:
anti-pErk1/2 (Thr
202/Tyr
234), anti-pZAP70 (Y
319), anti-pLAT
(Y
171), anti-pJNK (Thr
183/185), anti-pp38 (Thr
180/182), anti-IkBa,
anti-AKT, and anti-GSK3b-1 (all from Cell signaling), anti-
PLCc1( Y
783, Santa Cruz), anti-NF-ATc1 (Alexis/Axxora), anti-b-
actin (Sigma), anti-pVav (Y
174 Santa Cruz), and anti-pSLP76 (BD
Biosciences).
Calcium measurements
Purified T cells (2610
7 cells/ml) in RPMI medium (phenol-red
free; Invitrogen) containing 10% FCS were loaded with 5 mg/ml
Indo-1-AM (Molecular Probes) at 37uC for 45 min. After washing,
cells were incubated in RPMI medium supplemented with 10%
FCS (phenol-red free) at 37uC for an additional 45 min. The
measurement was performed on a FACSort
TM flow cytometer
(Becton Dickinson). The kinetics of the data was analyzed with
FlowJo software (TreeStar).
Sequencing
Blood was taken from 14 individuals Macaca mulatta (rhesus
monkey) and 11 individuals Macaca fascicularis (cynomolgus
monkey). The animals analyzed belong to different families and
were from different origins to avoid inbreeding effects. RNA from
blood cells was isolated using Paxgene RNA Blood Kit (Qiagen) in
combination with Paxgene Blood RNA tubes (Preanalytix). RNA
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cDNA was prepared by using SuperScript II (Invitrogen)
according to manufacturer’s instructions. RT-PCR with RNA as
template using GAPDH-specific primers confirmed the absence of
genomic DNA within all samples and controls with no template
confirmed specificity. Primers used for amplification were the
following (sequences listed in 59 to 39 orientation): GAPDH:
ACCACAGTCCATGCCATCAC and TCCACCACCCTGT-
TGCTGTA; CD28: CTCACACTTCGGGTTCCTCG and
GGTCATTTCCTATCCAGAGC. RT-PCR fragments were
sequenced both forward and reverse (MWG). Of note, there were
individual differences in the nucleotide sequences not resulting in
exchanged amino acids.
FACS Analysis
For FACS analysis TGN1412 was labeled using the Alexa
FlourH488 monoclonal labeling kit (Invitrogen/Molecular Probes)
according to the manufacturer’s instructions. Human and monkey
blood was stained with TGN1412-Alexa FlourH488 at the
indicated concentrations in a total volume of 50 ml. Human and
monkey cells were stained using the following antibodies: anti-
CD3-PE, -APC or -FITC, anti-CD4-PE, anti-CD8-FITC or -
PerCP (all from BD). After washing with FACS-buffer, samples
were incubated with blood lysing buffer (BD Pharm Lyse
TM) for
2–3 hours at 4uC and washed again. Cells were analyzed via Flow
cytometry (LSR
TM II; BD) and evaluated with DIVAH software.
One representative experiment out of three comparable experi-
ments is shown.
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